This systematic review and network meta-analysis of 601 eligible trials found that sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1 receptor agonists were ...

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor ...

The researchers found that individual SGLT-2 inhibitors showed similar cardiovascular effectiveness at clinically effective ...

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

Sotagliflozin offers significant benefits for individuals with Type 1 diabetes and chronic kidney disease, study finds. Read ...

Combined strategy is effective but questions remain The view that the hyperglycaemia associated with type 2 diabetes is ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...